Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC2014
Trial ID NCT03743246
Disease B-Cell Acute Lymphoblastic Leukemia | B-Cell Non-Hodgkin's Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017
Location approved US, Japan, EU, Switzerland, UK, Canada
Generation2nd
PhasePhase1|Phase2
Recruitment statusRecruiting
TitleA Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Year2018
CountryUnited States
Company sponsorCelgene
Other ID(s)JCAR017-BCM-004|U1111-1220-3324|2018-001246-34
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted geneanti‐CD19 single‐chain variable fragment; 4‐1BB costimulatory motif; CD3ζ T‐cell activation domain

Clinical Result

Cohort1: B-ALL
Administration route intravenous infusion
Pts 48
Age Child, Adult
Lymph depletion Yes
Cohort2: Mrd+ B-All
Administration route intravenous infusion
Pts 23
Age Child, Adult
Lymph depletion Yes
Cohort3: B-NHL
Administration route intravenous infusion
Pts 10
Age Child, Adult
Lymph depletion Yes

Relationship Graph

Overview of Knowledge Graph